pemetrexed (Rx)

Brand and Other Names:Alimta
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 100mg/vial
  • 500mg/vial
more...

Malignant Pleural Mesothelioma

Indicated for mesothelioma in combination with cisplatin in patients whose disease is unresectable or are not candidates for curative surgery

In combination with cisplatin: 500 mg/m² IV over 10 min on Day 1 q21Days 

Continue until disease progression or unacceptable toxicity

Nonsquamous Non-Small Cell Lung Carcinoma

Monotherapy

  • Maintenance
    • Indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy
    • 500 mg/m² IV over 10 min on Day 1 of q21Day; continue until disease progression or unacceptable toxicity after 4 cycles of platinum-based first-line chemotherapy 
  • Treatment
    • Also, indicated as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy
    • 500 mg/m² IV over 10 min on Day 1 of q21Day; continue until disease progression or unacceptable toxicity

Combination initial therapy

  • In combination with cisplatin
    • Indicated, in combination with cisplatin, for the initial treatment of patients with locally advanced or metastatic, nonsquamous NSCLC
    • 500 mg/m² IV over 10 min prior to cisplatin on Day 1 of q21Day for up to 6 cycles in the absence of disease progression or unacceptable toxicity 
  • In combination with carboplatin and pembrolizumab
    • Indicated, in combination with carboplatin and pembrolizumab, for the initial treatment of patients with metastatic, nonsquamous NSCLC
    • 500 mg/m² IV over 10 min prior to carboplatin on Day 1 of q21Day cycle for 4 cycles; following completion of platinum-based therapy, pemetrexed may be administered as maintenance therapy, alone or with pembrolizumab, until disease progression or unacceptable toxicity
    • Administer pembrolizumab prior to pemetrexed when given on the same day (refer to the full prescribing information for pembrolizumab and carboplatin)

Premedication Regimen

Folic acid: 400-1000 mcg PO qDay beginning 7 days before first pemetrexed dose; continue until 21 days after the last dose

Vitamin B12: 1 mg IM beginning 1 week before first pemetrexed dose and repeat every 3 cycles thereafter; subsequent doses may be administered on the same day as pemetrexed

Do not substitute PO B12 for IM (see Cautions)

Dexamethasone: 4 mg PO BID on the day before, day of, and day after pemetrexed administration treatment to help prevent skin rash

Dosage Modifications

Modification of ibuprofen dosing in patients with CrCl (45-79 mL/min)

  • Avoid administration of ibuprofen for 2 days before, day of, and 2 days following administration of therapy
  • Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant use of ibuprofen cannot be avoided

Delay initiation of the next cycle of pemetrexed until:

  • Recovery of nonhematologic toxicity Grade≤2; AND
  • Absolute neutrophil count (ANC)≥1500 cells/mm³ AND
  • Platelet count ≥100,000 cells/mm³

Adjust to 75% of previous dose

  • ANC <500/³ and platelets ≥50,000 cells/mm³
  • Platelet count <50,000 cells/mm³ without bleeding
  • Any Grade 3 or 4 nonhematologic toxicities EXCEPT mucositis or neurologic toxicity
  • Diarrhea requiring hospitalization

Adjust to 50% of previous dose

  • Platelet count <50,000 cells/mm³ with bleeding
  • Grade 3 or 4 mucositis

Discontinue

  • Recurrent Grade 3 or 4 myelosuppression after 2 dose reductions
  • Permanently discontinue
    • Grade 3 or 4 neurologic toxicity
    • Recurrent Grade 3 or 4 nonhematologic toxicity after 2 dose reductions
    • Severe and life-threatening skin toxicity
    • Interstitial pneumonitis

Renal impairment

  • CrCl (calculated by Cockcroft-Gault equation) ≥45 mL/min: No dosage adjustment necessary
  • CrCl <45 mL/min: No recommended dose; do not administer

Dosing Considerations

Combination therapy with carboplatin and pembrolizumab for the initial treatment of patients with metastatic, nonsquamous NSCLC; this indication is approved under accelerated approval based on tumor response rate and progression-free survival; continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials

Limitation of use: Pemetrexed is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer

Obtain complete blood cell count (CBC) on Days 1, 8, and 15 of each cycle; assess CrCl prior to each cycle

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and pemetrexed

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Nausea (19-56%)

            Fatigue (25-43%)

            Vomiting (9-40%)

            Anemia (15-33%)

            Neutropenia (6-29%)

            Anorexia (19-27%)

            Constipation (21%)

            Neutropenia, Grade 3 or 4 (3-15%)

            Stomatitis (7-14%)

            Diarrhea (12%)

            Alopecia (12%)

            Arthralgia (15%)

            Insomnia (24%)

            Upper respiratory tract infection (20%)

            Dysgeusia (20%)

            Cough (24%)

            Peripheral edema (22%)

            1-10%

            Thrombocytopenia (10%)

            Elevated creatinine (10%)

            Increased AST/ALT (1-10%)

            Rash/desquamation (7-10%)

            Thrombocytopenia, Grade 3 or 4 (4-9%)

            Febrile neutropenia, Grade 3 or 4 (1-9%)

            Diarrhea, Grade 3 or 4 (1-9%)

            Sensory neuropathy (9%)

            Taste disturbance (8%)

            Dehydration, thrombosis/embolism (7%)

            Fatigue, Grade 3 or 4 (5-7%)

            Nausea, Grade 3 or 4 (1-7%)

            Vomiting, Grade 3 or 4 (6%)

            Dysphagia/esophagitis/odynophagia (6%)

            Anemia, Grade 3 or 4 (3-6%)

            Infection with Grade 3 or Grade 4 neutropenia (0-6%)

            Dyspepsia\heartburn (5%)

            Pyrexia (1-5%)

            Dehydration (1-5%)

            Renal failure (1-5%)

            Conjunctivitis (1-5%)

            Neutropenia-other (3%)

            Anorexia, Grade 3 or 4 (2%)

            Allergic reaction/hypersensitivity (2%)

            Renal failure (2%)

            Constipation, Grade 3 or 4 (1%)

            Elevated creatinine, Grade 3 or 4 (1%)

            Stomatitis, Grade 3 or 4 (1%)

            <1%

            Esophagitis

            Arrhythmia

            Motor neuropathy

            Febrile neutropenia

            Erythema multiforme

            Chest pain

            Increased GGT

            Ventricular tachycardia

            Syncope

            Gastrointestinal obstruction

            Depression

            Renal failure

            Pulmonary embolism

            Postmarketing Reports

            Gastrointestinal: Colitis, pancreatitis

            Blood and lymphatic system: Immune-mediated hemolytic anemia

            General: Edema

            Injury, poisoning, and procedural complications: Radiation recall

            Respiratory: Interstitial pneumonitis

            Skin: Serious and fatal bullous skin conditions, Stevens-Johnson syndrome, and toxic epidermal necrolysis

            Previous
            Next:

            Warnings

            Contraindications

            History of severe hypersensitivity reaction to pemetrexed

            Cautions

            See Dosage Modifications

            Severe myelosuppression may occur resulting in a requirement for transfusions and which may lead to neutropenic infection; risk of myelosuppression is increased in patients who do not receive vitamin supplementation; initiate supplementation with oral folic acid and intramuscular vitamin B12 prior to first dose of therapy; continue vitamin supplementation during treatment and for 21 days after last dose to reduce severity of hematologic and gastrointestinal toxicity

            Therapy can cause severe, and sometimes fatal, renal toxicity

            Serious and sometimes fatal, bullous, blistering and exfoliative skin toxicity, including cases suggestive of Stevens-Johnson Syndrome/Toxic epidermal necrolysis can occur

            Serious interstitial pneumonitis, can occur with treatment; withhold therapy for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation; if pneumonitis confirmed, permanently discontinue therapy

            Radiation recall can occur with treatment in patients who have received radiation weeks to years previously; monitor patients for inflammation or blistering in areas of previous radiation treatment; permanently discontinue therapy for signs of radiation recall

            Based on findings from animal studies and its mechanism of action, therapy can cause fetal harm when administered to a pregnant woman; avoid pregnancy (see Pregnancy)

            Drug interactions overview

            • Pemetrexed is an OAT3/OAT4 substrate; ibuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures; data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celecoxib) would not inhibit the uptake of pemetrexed
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Based on findings from animal studies and its mechanism of action, therapy can cause fetal harm when administered to a pregnant woman; there are no available data in pregnant women; in animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during period of organogenesis was teratogenic, resulting in developmental delays and malformations at doses lower than recommended human dose of 500 mg/m²; advise pregnant women of the potential risk to a fetus

            Contraception

            • Therapy can cause fetal harm when administered to a pregnant woman because of potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment for at least 6 months after final dose
            • Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after final dose

            Infertility

            • Therapy may impair fertility in males of reproductive potential; it is not known whether these effects on fertility are reversible

            Lactation

            There is no information regarding presence of drug or its metabolites in human milk, effects on breastfed infant, or on milk production; because of potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 week after last dose

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Antifolate antineoplastic agent

            Disrupts folate-dependent metabolic processes essential for cell replication

            Distribution

            Vd (ss): 16.1 L

            Protein bound: 81%

            Metabolism

            Metabolites: polyglutamate forms

            Enzymes inhibited

            • Thymidylate synthase
            • Dihydrofolate reductase
            • Glycinamide ribonucleotide formyltransferase
            • All folate-dependent enzymes involved in de novo biosynthesis of thymidine and purine nucleotides

            Elimination

            Total body clearance: 91.8 mL/min

            Half-Life: 3.5 hr

            Excretion: Urine

            Previous
            Next:

            Administration

            IV Incompatibilities

            Solution: Do not use calcium-containing solutions for reconstitution, including LR & Ringer's

            Coadministration not recommended

            IV Compatibilities

            Solution: 0.9% NaCl

            IV Preparation

            Pemetrexed a cytotoxic drug; follow applicable special handling and disposal procedures

            Aseptically reconstitute pemetrexed to achieve a concentration (25 mg/mL) as follows: Reconstitute each 100-mg vial with 4.2 mL of 0.9% NaCl (preservative-free); reconstitute each 500-mg vial with 20 mL of 0.9% NaCl (preservative-free)

            Gently swirl until completely dissolved; resulting solution is clear and ranges in color from colorless to yellow/green-yellow without adversely affecting quality

            Visually inspect particulate matter and discoloration prior to further dilution If particulate matter is observed, discard vial

            Withdraw the calculated pemetrexed from the vial(s) and discard vial with any unused portion

            Further dilute reconstituted vial with 0.9% NaCl (preservative-free) to achieve a total volume of 100 mL for IV infusion

            IV Administration

            Infuse over 10 min

            Storage

            Unused vials: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)

            Reconstituted vials: Refrigerate 2-8°C (36-46°F) for no longer than 24 hr from the time of reconstitution; discard vial after 24 hr

            Diluted infusion: Refrigerate 2-8°C (36-46°F) for no more than 24 hr from the time of reconstitution; discard after 24 hr

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.